Häftad, Engelska, 2027
Theranostic Approaches in Nuclear Medicine as a Strategy to Overcome Cancer Treatment Resistance
Av Mariza Vorster, Mike Sathekge
Del i serien Novel approaches to overcome cancer resistance to conventional therapies
1990 kr
Beställningsvara. Skickas inom 11-20 vardagar. Fri frakt över 249 kr.
Beskrivning
- Examines the biological mechanisms underlying cancer treatment resistance and the role of theranostic strategies in overcoming these challenges
- Explores radiopharmaceutical design, molecular imaging, dosimetry, and personalised treatment planning to optimize radionuclide therapy outcomes
- Reviews combination and tandem treatment approaches across prostate cancer, breast cancer, and neuroendocrine tumours, highlighting current advances in precision nuclear medicine
Produktinformation
- Utgivningsdatum: 2027-06-01
- Mått: 191 x 235 x undefined mm
- Vikt: 450 g
- Format: Häftad
- Språk: Engelska
- Serie: Novel approaches to overcome cancer resistance to conventional therapies
- Antal sidor: 330
- Förlag: Elsevier Science
- ISBN: 9780443450525
Utforska kategorier
Mer om författaren
Prof Mariza Vorster is the Academic and Clinical Head of the Department of Nuclear Medicine at the University of KwaZulu-Natal, which spans three hospital sites in Durban. She began Ac-225-PSMA and DOTATATE therapy in KwaZulu-Natal in January 2023 and received the ICPO's Maurits W Geerlings award that year. In 2025 her department was accredited as an ICPO Theranostic Centre of Excellence. She is Immediate Past President of the College of Nuclear Physicians (2020 to 2026) and serves as an examiner, convenor and senator for the Colleges of Medicine of South Africa. She chairs the International Scientific Steering Committee for NuMeRI, serves as Secretary of the International Society of Radiolabelled Blood Elements (ISORBE), is an Ambassador for the Oncidium Foundation, and is a member of the UroTerag LATAM Global Expert Panel. Prof Vorster is an IAEA expert and collaborator and has authored and co-authored over 150 peer-reviewed publications. Her research interests include novel Ga-68 based tracer applications and theranostics aimed at solving important clinical problems. Professor Mike Sathekge is President and CEO of the Nuclear Medicine Research Infrastructure (NuMeRI) and Head of Nuclear Medicine at Steve Biko Academic Hospital and the University of Pretoria. He is internationally recognised for his leadership in radiotheranostics and targeted alpha therapy, having served as principal investigator on multiple early-phase studies. Mike Sathekge plays a key role in translational research at the interface of academia, healthcare systems, and industry, supporting the development, validation, and clinical adoption of novel radiopharmaceuticals. He has published extensively and is Editor-in-Chief of Seminars in Nuclear Medicine and providing strategic oversight of emerging scientific and clinical trends. He leads the IAEA Anchor Centre for Rays of Hope for cancer care in South Africa and is Co-Chair of the National Cancer Research Innovation Strategy (NCRIS). He currently serves as Chair of the Africa Health Research Institute (AHRI). Professor Sathekge is the recipient of numerous national and international honours.
Recensioner i media
Select Guide Rating
Betyg & recensioner
0 recensioner
Inga recensioner tillgängliga.